Dupilumab Treatment in Pemphigus: A Report of Three Cases and Literature Review

ABSTRACT Pemphigus vulgaris (PV) and foliaceus (PF) are rare autoimmune blistering diseases traditionally treated with systemic corticosteroids, immunosuppressants, intravenous immunoglobulins, and rituximab. Nonetheless, a subset of patients remains refractory or has contraindications to these conventional therapies. We present three cases of PV and PF treated with dupilumab. Two patients exhibited rapid clinical improvement. However, one patient with pemphigus foliaceus showed no response to dupilumab treatment, leading to its discontinuation. Recent reports have documented nine cases of pemphigus treated with dupilumab (six PV and three PF). The cases showed a rapid clinical improvement, although dosing regimens varied. One patient discontinued treatment due to lack of efficacy after 4 weeks of follow‐up. Dupilumab appears to be a promising therapeutic alternative for patients with PV and PF. Further studies are needed to evaluate its efficacy.